Eiropas Savienība - latviešu - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

bioveta, a.s., Čehija - erysipelothrix rhusiopathiae - emulsija injekcijām - cūkas

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - pulveris iekšķīgi lietojamas suspensijas pagatavošanai - 400 mg/57 mg/5 ml

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - pulveris iekšķīgi lietojamas suspensijas pagatavošanai - 400 mg/57 mg/5 ml

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 500 mg/125 mg

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline single member a.e.b.e., greece - aciklovīrs - pulveris infūziju šķīduma pagatavošanai - 250 mg

Latvija - latviešu - Zāļu valsts aģentūra

boehringer ingelheim international gmbh, germany - glihidons - tablete - 30 mg